GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its
initial public offering of 8,050,000 shares of its common stock at an
initial public offering price of $8.00 per share, which includes the
exercise in full by the underwriters of their option to purchase up to
1,050,000 additional shares of common stock. All of the shares in the
offering were offered by GlycoMimetics. The aggregate net proceeds to
GlycoMimetics, after underwriting discounts and commissions and
estimated offering expenses, are expected to be approximately $57.4
million.
Jefferies LLC and Barclays Capital Inc. acted as joint book-running
managers for the offering. Stifel acted as co-lead manager and Canaccord
Genuity Inc. acted as co-manager.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on January 9, 2014.
The offering was made only by means of a prospectus. A copy of the final
prospectus relating to these securities may be obtained from Jefferies
LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th
Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com
or by phone at 877-547-6340 or Barclays Capital Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
email at Barclaysprospectus@broadridge.com
or by phone at 888-603-5847.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. Glycomimetics are molecules that mimic the structure
of carbohydrates involved in important biological processes. Using its
expertise in carbohydrate chemistry and knowledge of carbohydrate
biology, GlycoMimetics is developing a pipeline of glycomimetic drug
candidates that inhibit disease-related functions of carbohydrates, such
as the roles they play in inflammation, cancer and infection.
Copyright Business Wire 2014